LB0003 Dazodalibep (VIB4920/HZN4920) in Sjögren's Subjects with an Unacceptable Symptom Burden: Safety and Efficacy from a Phase 2, Randomized, Double-Blind Study

• Published in: Annals of the rheumatic diseases Vol. 82; no. Suppl 1; p. 201
• Main Authors: St. Clair, E.W., Alevizos, I., Rees, W., Wang, L., Baer, A., Ng, W.F., Noaiseh, G., Baldini, C.
• Format: Journal Article
• Language: English
• Published: Kidlington Elsevier B.V 01.06.2023; Elsevier Limited
• Subjects: Autoimmune diseases; CD40L protein; Clinical trials; COVID-19; Diarrhea; Double-blind studies; Eye diseases; Fatigue; Gammopathy; Long COVID; Morbidity; Neutropenia; Pain; Patients; Placebos; Quality of life; Randomized control trial; Rhinopharyngitis; Safety; Sjogren's syndrome; Sjögren syndrome; Statistical analysis; Stockholders; Randomized control trial; Sjögren syndrome; Safety

Sjögren's is a systemic autoimmune disease associated with marked morbidity and poor health-related quality of life, generally driven by the cardinal symptoms of the disease: dryness, pain, and fatigue (assessed via EULAR Sjögren's Syndrome Patient Reported Index [ESSPRI]). The population...